King Pharmaceuticals (KG-$13.00) will likely face generic intrusion for its popular muscle relaxant Skelaxin by 2012. With little visible success in the development of a longer-acting formulation, the company has already shifted promotional efforts of its 610 person sales force to pain-relief products with more promising growth prospects, such as the non-steroidal anti-inflammatory (NSAID) Flector Patch and Embeda, the first of the new abuse-deterrent opioids to reach the U.S. market (so-called because the medication incorporates physical and pharmacological barriers to obtaining the euphoric effects of opioids).
CEO Markison informed investors at the JPMorgan Health Conference that the company remained on schedule with FDA timelines for two other promising tamper-resistant pain killer drugs. Nonetheless, the road to approvable action letters is littered with potholes….
Read More at BNET Pharma….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.
CEO Markison informed investors at the JPMorgan Health Conference that the company remained on schedule with FDA timelines for two other promising tamper-resistant pain killer drugs. Nonetheless, the road to approvable action letters is littered with potholes….
Read More at BNET Pharma….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.
No comments:
Post a Comment